Status:
COMPLETED
Full Thickness Macular Hole and Internal Limiting Membrane Peeling Study
Lead Sponsor:
University of Aberdeen
Collaborating Sponsors:
NHS Grampian
Chief Scientist Office of the Scottish Government
Conditions:
Stage 2 or 3 Full Thickness Macular Hole
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
A macular hole is a fairly common problem in the retina and is an important cause of loss of central vision. The aim of this study is to determine whether, in patients with a stage 2 or 3 full thickne...
Detailed Description
Idiopathic full-thickness macular hole (FTMH) is an important cause of loss of central vision, usually leading to severe visual impairment. Up to 20% of affected people will develop a FTMH in both eye...
Eligibility Criteria
Inclusion
- Idiopathic FTMH of stage 2-3, Duration of hole ≤18 months, Visual acuity equal to or worse than 20/40 in the study eye.
Exclusion
- Stage 1 or 4 FTMH, Stage 2-3 FTMH of \> 18 months duration, Visual acuity \>20/40 in study eye, FTMH related to high myopia (\>6 dioptres), FTMH related to trauma, any other causes of decreased vision (ie corneal scarring, age-related macular degeneration, diabetic retinopathy, glaucoma if central and/or paracentral absolute visual field defects present), patient unable to understand English, patient unable to give informed consent.
Key Trial Info
Start Date :
July 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2011
Estimated Enrollment :
141 Patients enrolled
Trial Details
Trial ID
NCT00286507
Start Date
July 1 2005
End Date
September 1 2011
Last Update
June 6 2012
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal Victoria Eye and Ear Hospital
Dublin, Ireland
2
Waterford Regional Hospital
Waterford, Ireland
3
Aberdeen Royal Infirmary
Aberdeen, United Kingdom
4
Bristol Eye Hospital
Bristol, United Kingdom